+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Type 2 Diabetes Drugs Market by Drug, Application, Distribution - Global Forecast 2025-2030- Product Image
Type 2 Diabetes Drugs Market by Drug, Application, Distribution - Global Forecast 2025-2030- Product Image
Sale

Type 2 Diabetes Drugs Market by Drug, Application, Distribution - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5666390
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Type 2 Diabetes Drugs Market grew from USD 71.17 billion in 2023 to USD 77.07 billion in 2024. It is expected to continue growing at a CAGR of 8.81%, reaching USD 128.55 billion by 2030.

The scope of the Type 2 diabetes drugs market encompasses a variety of therapeutic classes, including biguanides, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. These drugs aim to manage blood glucose levels, thus preventing complications associated with Type 2 diabetes. The necessity of these therapeutics is underscored by the rising prevalence of Type 2 diabetes due to factors such as aging populations, unhealthy diets, and sedentary lifestyles. Their application spans across oral administration, injections, and other delivery modes targeting efficient glucose control, with end-use primarily among healthcare providers such as hospitals, clinics, and home care settings. Key growth factors include advancements in drug formulation, the increasing incidence of diabetes, and growing awareness of diabetes management. Opportunities abound in developing cost-effective, patient-friendly drug delivery mechanisms and personalized treatment plans leveraging AI and genomic data. A significant opportunity lies in emerging markets with underpenetrated healthcare systems. However, limitations include stringent regulatory requirements, high drug development costs, and potential side effects that may limit wider adoption. Another challenge is the significant competition from generic counterparts, which pressures pricing strategies. Market players should focus on innovations such as fixed-dose combinations, novel biological targets, and minimally invasive delivery systems to stay competitive. Moreover, ongoing research on the pathophysiology of diabetes can lead to the discovery of novel therapeutic classes that offer better efficacy and fewer side effects. There's also an emerging opportunity in developing integrative care models that combine pharmaceutical interventions with digital health tools designed for continuous glucose monitoring and patient engagement. The market is dynamic and competitive, requiring sustained investment in research and development, alongside strategic partnerships and collaborations, to maintain a competitive edge and drive growth in this critical healthcare sector.

Understanding Market Dynamics in the Type 2 Diabetes Drugs Market

The Type 2 Diabetes Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Significance of diabetic prevalence globally
    • Rise in obesity population coupled with unhealthy diets and sedentary lifestyles
    • Government initiatives and programs to create health awareness
  • Market Restraints
    • Products recall affecting brand reputation
  • Market Opportunities
    • Advancements in diabetic medications by pharmaceutical manufacturers
    • Rising investment in R&D and healthcare infrastructure development
  • Market Challenges
    • Stringent regulatory environment and time-consuming approval process

Exploring Porter’s Five Forces for the Type 2 Diabetes Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Type 2 Diabetes Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Type 2 Diabetes Drugs Market

External macro-environmental factors deeply influence the performance of the Type 2 Diabetes Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Type 2 Diabetes Drugs Market

The Type 2 Diabetes Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Type 2 Diabetes Drugs Market

The Type 2 Diabetes Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Type 2 Diabetes Drugs Market

The Type 2 Diabetes Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Type 2 Diabetes Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca, Bayer Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Peptron, Pfizer Inc., and Sanofi Group.

Market Segmentation & Coverage

This research report categorizes the Type 2 Diabetes Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug
    • Injectables
      • Aspart
      • Exenatide
      • Glargine
      • Insulin
      • Leraglutide
      • Pramlintide
    • Oral
      • Alpha-Glucosidase Inhibitors
      • Biguanides
      • Dipeptidyl Peptidase-4 Inhibitors
      • Glucagon-Like Peptide
      • Receptor Agonists
      • Secretagogues
      • Sodium Glucose Cotransport 2 Inhibitors
      • Sulfonylureas
      • Thiazolidinediones
  • Application
    • Cardiovascular Safety
    • Glycemic Control
    • Hypoglycemia Avoidance
  • Distribution
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Significance of diabetic prevalence globally
5.1.1.2. Rise in obesity population coupled with unhealthy diets and sedentary lifestyles
5.1.1.3. Government initiatives and programs to create health awareness
5.1.2. Restraints
5.1.2.1. Products recall affecting brand reputation
5.1.3. Opportunities
5.1.3.1. Advancements in diabetic medications by pharmaceutical manufacturers
5.1.3.2. Rising investment in R&D and healthcare infrastructure development
5.1.4. Challenges
5.1.4.1. Stringent regulatory environment and time-consuming approval process
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Type 2 Diabetes Drugs Market, by Drug
6.1. Introduction
6.2. Injectables
6.2.1. Aspart
6.2.2. Exenatide
6.2.3. Glargine
6.2.4. Insulin
6.2.5. Leraglutide
6.2.6. Pramlintide
6.3. Oral
6.3.1. Alpha-Glucosidase Inhibitors
6.3.2. Biguanides
6.3.3. Dipeptidyl Peptidase-4 Inhibitors
6.3.4. Glucagon-Like Peptide
6.3.5. Receptor Agonists
6.3.6. Secretagogues
6.3.7. Sodium Glucose Cotransport 2 Inhibitors
6.3.8. Sulfonylureas
6.3.9. Thiazolidinediones
7. Type 2 Diabetes Drugs Market, by Application
7.1. Introduction
7.2. Cardiovascular Safety
7.3. Glycemic Control
7.4. Hypoglycemia Avoidance
8. Type 2 Diabetes Drugs Market, by Distribution
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Type 2 Diabetes Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Type 2 Diabetes Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Type 2 Diabetes Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. TYPE 2 DIABETES DRUGS MARKET RESEARCH PROCESS
FIGURE 2. TYPE 2 DIABETES DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. TYPE 2 DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. TYPE 2 DIABETES DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DIPEPTIDYL PEPTIDASE-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECRETAGOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORT 2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CARDIOVASCULAR SAFETY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYCEMIC CONTROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HYPOGLYCEMIA AVOIDANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 51. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 52. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 53. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 54. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 57. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 58. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 59. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 78. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 79. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 80. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 81. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 83. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 84. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 85. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 86. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 89. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 93. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 94. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 95. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 96. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 99. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 100. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 101. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 104. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 105. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 106. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 109. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 110. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 111. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 114. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 115. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 116. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 119. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 120. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 121. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 123. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 124. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 125. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 126. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 129. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 130. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 131. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 139. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 140. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 141. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 142. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 144. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 145. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 146. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 147. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 149. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 150. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 151. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 152. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 154. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 155. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 156. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 157. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 159. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 160. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 161. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 162. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 165. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 166. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 167. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 169. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 170. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 171. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 172. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 180. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 181. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 184. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 185. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 186. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 187. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 189. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 190. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 191. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 192. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 194. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 195. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 196. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 197. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 214. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 215. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 216. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 217. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 220. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 229. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 230. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 231. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 232. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 242. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 244. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 245. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Type 2 Diabetes Drugs Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca
  • Bayer Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Peptron
  • Pfizer Inc.
  • Sanofi Group

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 77.07 Billion
Forecasted Market Value ( USD ) by 2030 $ 128.55 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

Diabetes Drugs Market by Product, Application, Distribution Channel - Global Forecast 2025-2030 - Product Image

Diabetes Drugs Market by Product, Application, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Type 1 Diabetes Drug Market by Form, End User - Global Forecast 2025-2030 - Product Image

Type 1 Diabetes Drug Market by Form, End User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Type (Type 1, Type 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Type (Type 1, Type 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 100 Pages
  • Global
From
Diabetes Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Diabetes Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Oral Anti-Diabetic Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029 - Product Image

Oral Anti-Diabetic Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

  • Report
  • 150 Pages
  • Global
From

About the Type 2 Diabetes Drug Market

The Type 2 Diabetes Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat Type 2 Diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin properly. Type 2 Diabetes Drugs are used to help control blood sugar levels, reduce the risk of complications, and improve overall health. These drugs can be taken orally, injected, or inhaled. Common Type 2 Diabetes Drugs include Metformin, Sulfonylureas, Thiazolidinediones, Meglitinides, DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors. Some companies in the Type 2 Diabetes Drug market include Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, Boehringer Ingelheim, and Takeda. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.